Ignite Creation Date:
2025-12-25 @ 3:37 AM
Ignite Modification Date:
2026-03-03 @ 3:05 PM
Study NCT ID:
NCT00093002
Status:
COMPLETED
Last Update Posted:
2008-06-12
First Post:
2004-09-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Early Breast Cancer | View |
| None | neoadjuvant therapy | View |
| None | hormonal treatment | View |
| None | newly diagnosed breast cancer | View |
| None | Estrogen Receptor Positive Breast Cancer | View |
| None | treatment naïve | View |
| None | neoadjuvant treatment | View |
| None | neoadjuvant setting | View |
| None | invasive breast cancer | View |